Last reviewed · How we verify

Vivarin

King Saud University · FDA-approved active Small molecule

Vivarin is a Small molecule drug developed by King Saud University. It is currently FDA-approved. Also known as: 1,3,7-Trimethylpurine-2,6-dione, C8H10N4O2, caffeine citrate.

At a glance

Generic nameVivarin
Also known as1,3,7-Trimethylpurine-2,6-dione, C8H10N4O2, caffeine citrate
SponsorKing Saud University
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vivarin

What is Vivarin?

Vivarin is a Small molecule drug developed by King Saud University.

Who makes Vivarin?

Vivarin is developed and marketed by King Saud University (see full King Saud University pipeline at /company/king-saud-university).

Is Vivarin also known as anything else?

Vivarin is also known as 1,3,7-Trimethylpurine-2,6-dione, C8H10N4O2, caffeine citrate.

What development phase is Vivarin in?

Vivarin is FDA-approved (marketed).

Related